文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

大规模药物基因组检测实施:氟嘧啶治疗前二氢嘧啶脱氢酶检测

Implementation of mass pharmacogenetic testing: Dihydropyrimidine dehydrogenase testing prior to fluoropyrimidine treatment for patients.
PubMed 文献 · Br J Clin Pharmacol · 2025-04-27

该研究通过问卷调查评估英国氟嘧啶化疗前DPYD检测的实施情况,131/138(94.9%)机构报告对所有患者进行检测,但样本送检实验室和周转时间存在差异,结论认为检测已成功实施但需标准化端到端周转时间并制定最佳实践路径。

要点

  • 英国94.9%的机构在氟嘧啶化疗前对所有患者进行DPYD检测。
  • 检测可由肿瘤医生、护士、药师等多学科人员申请并处理结果。
  • 自报周转时间从<2天(实验室与化疗中心同址)到>10天不等。

核心结论

  • 通过多专业全国协作,DPYD检测已成功实施,但需标准化和改善端到端周转时间,并已制定最佳实践路径。

研究设计与样本

  • 由英国国家DPYD工作组开发并批准问卷,于2021年6月至9月发放给基因组医学服务联盟临床主任和药学高级负责人员,邀请全英所有提供氟嘧啶的医院参与。

主要发现

  • 131/138(94.9%)机构报告对所有接受氟嘧啶的患者进行检测。
  • 英格兰76.7%的医院将样本送至中央委托的基因组实验室,权力下放地区73.9%送至区域基因组实验室。
  • 检测申请和结果处理由肿瘤医生、独立非医疗处方者、临床护士专家、筛查药师和化疗护士等多学科人员完成。
  • 自报周转时间从<2天(区域实验室与化疗中心同址)到>10天不等。

临床怎么用

  • 氟嘧啶化疗前应实施DPYD检测,并由多学科团队协作完成检测申请和结果处理。
  • 需关注检测周转时间,参考最佳实践路径优化端到端流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pharmacogenomics enables personalization of drug therapy improving effectiveness and/or safety. Dihydropyrimidine dehydrogenase [DPYD] testing prior to fluoropyrimidine chemotherapy was commissioned by NHS England in response to an update from the Medicines and Healthcare products Regulatory Agency. METHODS: A questionnaire developed and approved by the National DPYD Working Group investigated processes of testing, receiving and responding to results. The survey was distributed to Genomics Medicine Service Alliance (GMSA) Clinical Directors and Pharmacy Senior Responsible Officers for dissemination in their geography. Data were collected June-September 2021. All hospitals delivering fluoropyrimidines across the UK were invited to participate. RESULTS: 131/138 (94.9%) organizations reported testing all patients receiving fluoropyrimidines. In England 76.7% of hospitals sent samples to centrally commissioned genomics laboratories. In the devolved nations, 73.9% sent samples to regional genomics laboratories. Multidisciplinary staff including oncologists, independent non-medical prescribers, clinical nurse specialists, screening pharmacists and chemotherapy nurses requested the test, checked and actioned the result. Self-reported turnaround times varied from <2 days where a regional laboratory was colocated with a chemotherapy centre to >10 days. CONCLUSION: Through multiprofessional, national collaboration, this is the first report studying the large-scale rollout of a nationally commissioned pharmacogenetic test. Whilst DPYD testing has been successfully implemented, there is a need to standardize and improve end-to-end turnaround times. This has led to the development of a best practice pathway. Critically, GMSAs must build on this implementation to deliver its priorities, in supporting equitable access to future pharmacogenomic testing across a wider cohort of therapies.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Shaunak N, Keen J, Kim A, et al. Implementation of mass pharmacogenetic testing: Dihydropyrimidine dehydrogenase testing prior to fluoropyrimidine treatment for patients. Br J Clin Pharmacol. 2025. PMID: 40289265. doi:10.1002/bcp.70057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。